Introduction
Colon cancer is the third most common cancer worldwide and the third leading cause of cancer death in both men and women in the U.S., with approximately 150,000 new cases diagnosed and 50,000 disease related deaths every year (1) . Like most cancers, early diagnosis and surgery significantly improve the chances of cure for colon cancer (2) .
Therefore the development of serum-based biomarkers and novel therapeutic targets for treating colorectal cancer are greatly needed.
High density lipoprotein (HDL) is an important mediator of lipid homeostasis. HDL and HDL associated molecules (proteins and lipids) provide a number of protective functions including anti-inflammatory, antioxidant, anti-microbial, and innate immunity (3) . HDL cholesterol (HDL-C) is an accepted marker for cardiovascular risk assessment (4) and several clinical strategies for cardiovascular therapy are designed to elevate HDL-C (5-6). Although there is significant correlation between lipid metabolism and cancer, until recently very little is known about the potential role for lipoproteins in cancer biology. There is a significant inverse association between HDL-C and the risk of incident cancer, which is independent of low density lipoprotein cholesterol (LDL-C), age, BMI and smoking status (7) . The concentrations of HDL and apolipoprotein A-I (apoA-I, the major protein component of HDL) were found to be inversely associated with the risk of colon cancer (8-9).
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HDL involves treatment with HDL mimetic peptides (11) . Our previous studies showed that apoA-I is a biomarker for detection of early stage ovarian cancer and a promising therapeutic target for the treatment of ovarian cancer (12) (13) (14) (15) (16) (17) .
In the present study, we demonstrate that two HDL mimetics, the apoA-I mimetic well culture plates, and 24 hours later the medium was replaced with serum free medium.
Following an overnight incubation, the cells were either treated with vehicle (control), or treated with 10 μg/mL of either L-4F or G* peptide. The peptides were dissolved in H2O.
Cells were incubated for an additional 48 hours and assayed for viability using the MTS assays kit (Promega) according to the manufacturer's protocol. For proliferation assay, cells were labeled with BrdU for the last 4 hours of the 48 hours incubation. Cells were subsequently washed, fixed, and incubated with mouse anti-BrdU antibody for 1 hour at room temperature and detected by a peroxidase-coupled goat anti-mouse secondary antibody (Calbiochem). Absorbance was measured using dual wavelengths 450 and 540 nm.
Tumor-Load Study
6-week-old BALB/c female mice were given a 100 μL subcutaneous injection of 1 × 10 6 CT26 cells prepared as a single cell suspension in PBS, and the mice were treated with sc-4F or L-4F at 10 mg/kg administered subcutaneously (SQ) daily for 15 days. The mice were sacrificed and tumor weights were measured.
Pulmonary Metastasis in Vivo.
BALB/c mice were intravenously injected with 2 x 10 4 CT26 cells in 100 μL of PBS via tail vein injection and the mice were treated with L-4F or sc-4F at 10 mg/kg/day administered SQ for 3 weeks; or treated with sc-4F or L-4F or G* peptide at 100mg/kg /day administered in a chow diet for 3 weeks. After 3 weeks treatment, the mice were sacrificed; lungs were harvested, weighed and fixed with Bouin's solution (Sigma).
Tumor nodules on the lung surface were counted. male mice on a C57BL/6J background were treated with L-4F or sc-4F at 100mg/kg/day administered in a chow diet. After 8 weeks treatment, mice were sacrificed. The entire intestine was immediately removed, fixed in formalin and 70% ethanol. The intestine was opened and examined under a dissecting microscope to count and measure the tumors.
Immunohistochemistry (IHC) Staining
Tumor tissues from the lung surface were fixed and embedded with paraffin, sectioned at 5μm thickness. Sections were deparaffinized with xylene, rehydrated with 100%, 90%, 70%, and 50% ethanol, treated with proteinase K at 20 μg/mL for 30 min, and treated with 3% H 2 O 2 for 30 min at room temperature to inhibit endogenous peroxidase, blocked with 10% normal goat serum and 4% BSA prepared in PBS for 3 h, and then incubated with 1:50 rat anti-mouse monoclonal CD31 antibody overnight at 4 o C. The sections were incubated with corresponding biotinylated secondary antibody for 1 hour, followed by incubation with Vectastain ABC Elite reagents. 9 containing 40 μg/mL RNaseA and 100 μg/mL Propidium Iodide, and subjected to flow cytometric cell-cycle analysis by FACScan from BD Biosciences.
Western Blot Analysis
Total cell proteins were collected after treatment in cell lysis buffer containing 0.1M NaCl, 5 mM EDTA, 50 mM sodium orthovanadate, 1% Triton X-100, and protease inhibitor tablet in 50 mM Tris buffer (pH 7.5). 20 μg of total proteins were separated by SDS-PAGE and transferred onto nitrocellulose membrane, and followed by incubation with primary antibody at 4°C in 5% skim milk and 0.1% Tween-20. Anti-Cyclin D1 and anti-Cyclin A rabbit polyclonal antibodies were used at 1:1000 dilution, and anti-β-actin molyclonal antibody was used at 1:2000 dilution.
ELISA Analysis
Il-6 concentrations were measured in plasma by a competition ELISA according to the manufacture's protocol (Invitrogen).
LPA Binding Affinity and Serum LPA Levels
LPA (20:4) was purchased from Avanti Polar Lipids. LPA levels were determined as described previously (19) .
Statistical Analyses
The data are shown as means ± SD for each group. We performed statistical analyses by unpaired t test. All results were considered statistically significant at P < 0.05. CT26 is a colon adenocarcinoma cell line which develops metastatic pulmonary tumors when introduced intravenously into immunocompetent BALB/c mice (20) (21) (22) . CT26 cell line has been widely used as a syngeneic tumor model to study therapeutic applications for cancer in mouse models and therefore we chose CT26 cells for the colon cancer study in our HDL mimetic studies. We first examined the effect of L-4F and sc-4F (a scrambled peptide containing the same amino acids as in the 4F peptide but arranged in a sequence that prevents the formation of a class A amphipathic helix) administered SQ at 10 mg/kg/day for 3 weeks on lung tumor formation in BALB/c mice injected with 2 X10 4 CT26 cells via tail vein. The lung weights (Fig 1A) and the tumor numbers counted on the lung surface (Fig 1B) in BALB/c mice treated with L-4F (n=11 per group) were significantly reduced compared with mice treated with sc-4F (280 mg vs. 225 mg, P < 0.01; 33 vs.18, P < 0.001). Representative photographs of lung tumors from the two groups are shown in Figure 1C . We next examined whether L-4F treatment effects the development of tumors in the flanks of BALB/c mice. 6-week-old BALB/c female mice were injected with 1x10 tumors from the two groups are shown in Figure 1E . We also measured IL-6 levels in plasma from the experiment shown in Fig 1A. IL-6 was significantly decreased in mice with L-4F treatment compared to control group (Fig 1F) .
Tumor development following CT26 cell injection is significantly decreased in mice that were treated with L-4F administered in mouse chow.
We recently reported that 4F is effective in animal models of atherosclerosis whether administered SQ or orally (18) . To determine whether L-4F could reduce tumor development when administered orally, BALB/c mice were injected with 2 x 10 4 CT26 cells via tail vein, and treated with L-4F (n=9) or sc-4F (n=12) at 100 mg/kg/day administered in the chow diet for 3 weeks. The lung weights (Fig 2A) and the tumor numbers ( Fig 2B) in BALB/c mice treated with sc-4F were significantly larger compared with mice treated with L-4F (296 mg vs. 238 mg, P < 0.05; 21 vs. 12, P < 0.0001). We previously reported that L-4F inhibits angiogenesis in vivo (23) . IHC staining of tumor sections from this experiment showed a significant decrease in CD31 expression in tumors derived from mice treated with L-4F compared to control mice ( Fig 2C) .
Furthermore, plasma LPA levels were significantly reduced in mice receiving L-4F peptide compared with their corresponding control mice, P < 0.01 ( Fig 2D) . or sc-4F (n=6) at 100 mg/kg/day administered in mouse chow for 8 weeks. The tumor numbers and sizes in the intestinal tract from mice treated with L-4F were significantly reduced compared with mice treated with sc-4F (100% vs. 60%, P < 0.05; 1-3 mm: 56.5 vs. 36.8, P < 0.05; >3 mm: 12.8 vs. 5, P < 0.05) (Fig 3A and 3B) . Plasma LPA levels from this experiment were significantly reduced in mice receiving L-4F peptide compared with to control mice, P < 0.01 (Fig 3C) .
L-4F alters CT26 cell viability, proliferation, cell cycle, and expression of cell cycle related proteins in vitro.
To examine the mechanisms by which HDL mimetic, L-4F inhibits CT26 cell-mediated tumor development in mice, the effect of L-4F on CT26 cell viability was determined in vitro. Cell viability was reduced by more than 25% (P < 0.001) in CT26 cells that were treated with L-4F (10 μg/mL) when compared with control ( Fig 4A) . Moreover, L-4F significantly inhibited proliferation of CT26 cells (P < 0.001) as measured by BrdU incorporation (Fig 4B) . To investigate whether L-4F inhibited cell proliferation through changes in cell cycle progression, the effect of L-4F on the cell cycle profile was assessed in CT26 cells. Cell cycle analysis demonstrated that L-4F treatment for 48 hours induced an increase in G0/G1 phase and arrest in S phase (Fig 4C) . Moreover, Western blot analysis demonstrated that expression of the cell cycle proteins Cyclin D1 and Cyclin A were significantly lower in cells treated with L-4F (Fig 4D) . LPA has been identified as an important mediator of tumor development, progression, and metastases in humans (26) (27) . We have previously demonstrated that apoA-I mimetic peptides inhibit LPA-induced proliferation of ID8 cells and reduce serum LPA levels in mice injected with ID8 cells (17) . L-4F binds LPA (17) , as expected, LPA (10-20 μM) significantly improved CT26 cell growth, and L-4F significantly reduced LPAinduced viability at all doses tested, P < 0.001 (Fig 5A) . We measured LPA levels in cell culture medium by LC/MS and found that LPA 16:0 and 18:0 were significantly decreased with L-4F treatment compared with the control medium. LPA 20:4 and 18:1
HDL mimetic L-4F inhibits LPA-induced proliferation of CT26 cells.
were not detectable in cell culture medium (Fig 5B) . Pulmonary tumor development following CT26 cell injection was significantly decreased in mice treated with G* peptide at 100 mg/kg/day administered in mouse chow for 3 weeks (Lung weights were 296 mg vs. 250mg, P < 0.05; tumor numbers were 21 vs.10, P < 0.0001) (Fig 6A, 6B) . Cell viability was ~ 40% lower in CT26 cells treated with G* peptide (10 μg/mL) when compared with no treatment (Fig 6C) . In the mouse experiment shown in Fig 6A and 6B , plasma LPA levels were significantly reduced in mice receiving G* peptide compared with their corresponding control mice P < 0.05 (Fig 6D) . Western Blot showed the expression of Cyclin D1 and Cyclin A was lower with G* peptide treatment compared with no treatment (Fig 6E) . 
Discussion
There is a significant correlation between lipid metabolism and cancer, and inflammatory oxidative stress has long been thought to be associated with the pathophysiology of cancer (28-30). Lipid oxidation and resulting oxidized lipid mediated inflammation appear to be common to the etiology of a number of inflammatory diseases (44) achieved very high plasma levels but did not achieve any improvement in HDL antiinflammatory properties. It was concluded that the doses needed for improving HDL function in humans maybe much higher than those used by Watson et al (44) and at least as high as those used by Bloedon et al (43) . Recently, Navab et al. (45) reported that the dose of the HDL mimetic peptide 4F that was administered and not the plasma level peptide regardless of the route of administration. Our results show that the HDL mimetics are effective whether given orally or SQ in mouse models at doses greater than those used by Bloedon et al (43) . Given our results with HDL mimetics in mouse colon cancer models and the results of Navab et al. (45) indicating that dose determines efficacy and not plasma levels, it will be important to test the high doses used here in any future clinical trials.
One of the downstream targets for the general mechanism of anti-tumorigenic activity of HDL mimetics appears to be angiogenesis as seen by the reduction in CD31 staining in treated tumors. LPA plays an important role in inflammation, angiogenesis, and cancer, and has become a promising target for therapy (46) . Moreover, consistent with our previous findings (17, 23) and current findings, the binding and removal of proinflammatory/pro-angiogenic lipids such as LPA may be a major part of the mechanism of action for the HDL mimetics. 
